Truist Financial initiated coverage on shares of Genmab A/S (NASDAQ:GMAB – Get Free Report) in a note issued to investors on Wednesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $40.00 price target on the stock. Truist Financial’s price target suggests a potential upside of 48.75% from the stock’s current price.
Other analysts have also recently issued research reports about the company. BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. HC Wainwright cut their price target on Genmab A/S from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Thursday, April 30th. The Goldman Sachs Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. Wolfe Research initiated coverage on shares of Genmab A/S in a research note on Friday, March 27th. They issued an “outperform” rating and a $32.00 price objective on the stock. Finally, Wall Street Zen downgraded shares of Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and an average price target of $37.93.
Check Out Our Latest Stock Report on Genmab A/S
Genmab A/S Price Performance
Institutional Trading of Genmab A/S
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Summitry LLC raised its stake in shares of Genmab A/S by 5.3% in the first quarter. Summitry LLC now owns 11,170 shares of the company’s stock worth $300,000 after buying an additional 567 shares during the period. BankChampaign National Association purchased a new position in shares of Genmab A/S during the 1st quarter valued at about $687,000. Strategic Investment Advisors MI bought a new position in shares of Genmab A/S during the 1st quarter valued at approximately $137,000. EverSource Wealth Advisors LLC increased its holdings in Genmab A/S by 51.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,597 shares of the company’s stock worth $123,000 after acquiring an additional 1,565 shares in the last quarter. Finally, Royal Bank of Canada increased its holdings in Genmab A/S by 1.8% in the 1st quarter. Royal Bank of Canada now owns 150,135 shares of the company’s stock worth $4,029,000 after acquiring an additional 2,637 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.
About Genmab A/S
Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.
Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.
Featured Articles
- Five stocks we like better than Genmab A/S
- Modine’s $4B AI Coup Freezes Out the Competition
- What Investors Need to Know About TSMC’s Hefty 17% Dividend Increase
- The SpaceX IPO Frenzy Is Creating 2 Very Different Bets
- AI Can’t Reach the Real World Without These 3 Stocks
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
